Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization

Sponsor
Rabin Medical Center
Study ID
NCT02797704
Phase
PHASE1/PHASE2
Status
Terminated

Conditions

  • Corneal Neovascularization

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Aflibercept — DRUG
    Eylea (aflibercept) Injection is a prescription medicine administered by injection into the eye.

Study Details

The goal of this current study is to prospectively evaluate the influence of a single subconjunctival aflibercept injection on the regression of corneal neovascularization. Twenty patients with corneal neovascularization who are candidates for anti VEGF treatment (by the discretion of a corneal specialist) will be included in this study. The patients will be treated with a single subconjunctival injection of 0.08 ml aflibercept (25 mg/ml) in a single quarter of the conjunctiva, near the limbus in a proximity to the area of pathological neovascularization. Regression of neovascularization will be documented.

Key Dates

Start date
Mar 2, 2017
Status verified
May 2016
Primary completion
Sep 4, 2019
Completion
Sep 10, 2019

Study Design

Enrollment
6 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: SC Aflibercept
    The patients will be treated with a single subconjunctival injection of 0.08 ml aflibercept (25 mg/ml) in a single quarter of the conjunctiva, near the limbus in a proximity to the area of pathological neovascularization

Primary Outcome Measure

Regression (change from baseline) of neovascularization clinically assessed by a corneal specialist [ Time Frame: 3 months (90 days), with repeat assessment at different follow up times at 7,14,30,60 and 90 days. ]

Related Studies